Valneva Announces End of Phase 2 Meeting with the FDA for its Chikungunya Vaccine Candidate

NEXT STORY
Luigi Franciosi to Advise on New Asthma & COPD Drug Development Programs for Vicenna Pharmaceuticals Inc.
PREV STORY
DIAGNOS AI based clinical Eye Test for Diabetic Retinopathy Demonstrates Exceptional Performance at the CHUM, expands for an Additional Six Months
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Cancer Genetics Announces $17.5 Million Common Stock Offering Priced At-the-Market under Nasdaq Rules

author_avatar
NASDAQ Market News

Aptose Biosciences and CrystalGenomics Announce Exclusive Agreement for Non-Covalent BTK / FLT3 / AURK Inhibitor

TORONTO and SEOUL, South Korea, June 08, 2016 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ...

author_avatar
NASDAQ Market News

UroGen Pharma Announces Presentation of Results from Interim Analysis of Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel™) for Non-Surgical Treatment of Upper Tract Urothelial Cancer (UTUC)

RA’ANANA, Israel and NEW YORK, April 03, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. ...

author_avatar
NASDAQ Market News